homepage-top-section

US-based pharmaceutical company Xeris Pharmaceuticals has agreed to acquire Strongbridge Biopharma in a stock and contingent value rights (CVRs) transaction valued at approximately $267m. Strongbridge is a commercial-stage

The Ministry of Health, Labour and Welfare (MHLW) of Japan has granted emergency use authorization for Covid-19 vaccines developed by AstraZeneca and Moderna. AstraZeneca’s Vaxzevria (ChAdOx1-S [Recombinant]), co-invented

GlaxoSmithKline (GSK) has agreed to divest the complete stake in its respiratory drug partner Innoviva for about $392m, or $12.25 per share. Under the terms of a definitive

Exscientia has expanded its partnership with Bristol-Myers Squibb (BMS) to leverage artificial intelligence (AI) to discover small molecule drug candidates across oncology and immunology, among other therapeutic areas.

As part of the agreement, BMS will pay $200m upfront to Agenus, which is also eligible for up to $1.36bn in development, regulatory and commercial milestone payments and

The agreement also covers additional payments of up to $57.5m contingent on future performance. Charles River expects the deal to boost its gene therapy capabilities for viral vectors

The Central Drugs Laboratory cleared the first batch of Sputnik V doses that reached India earlier this month. Under the pilot, a soft launch has begun, and the

Besides acquiring the exclusive rights to commercialise PRG1801 in India, Dr. Reddy’s will be responsible for future development including clinical trials, in the country. Pregene will be the sole supplier

The Russian Direct Investment Fund (RDIF) has announced that a single dose Covid-19 vaccine called Sputnik Light, obtained authorisation for use in the country. With recombinant human adenovirus